TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Firm”) (NASDAQ: MDNA TSX: MDNA), a medical stage immuno-oncology firm, at the moment introduced the voting outcomes from the Firm’s annual assembly of shareholders held at the moment, September 21, 2022 (the “Assembly”).
Medicenna is happy to announce that all the nominees listed within the administration proxy round dated August 2, 2022 have been elected as administrators. Every of the administrators was elected with larger than 97% of the votes forged by shareholders current on the today techs Assembly or represented by proxy. The outcomes of the vote are detailed beneath:
|Nominee||Votes For||% of
In opposition to
|% of Votes
In opposition to
|Dr. Fahar Service provider||24,859,038||97.878||538,956||2.122|
|Mr. Albert Beraldo||24,877,225||97.950||520,768||2.050|
|Ms. Karen Dawes||24,902,175||98.048||495,818||today techs ; border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; “>1.952|
|Dr. John (Jack) Geltosky||24,728,697||97.365||669,296||2.635|
|Ms. Rosemina Service provider||today techs black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; “>24,653,185||97.067||744,808||2.933|
|Dr. Chandrakant Panchal||24,820,996||97.728||576,997||2.272|
|Dr. John Sampson||24,840,678||97.806||today techs solid black 1pt ; border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; “>557,315||2.194|
Medicenna shareholders additionally voted to nominate PricewaterhouseCoopers LLP as auditor of the Firm.
A complete of 57.468% of the issued and excellent widespread shares of the Firm have been represented in particular person and by proxy on the Assembly.
Medicenna is a medical stage immunotherapy firm centered on today techs the event of novel, extremely selective variations of IL-2, IL-4 and IL-13 Superkines and first in school Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding with out CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating most cancers killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Biuseful ShigherOkine ImmunoTremedys) is designed to boost the power of Superkines to deal with immunologically “chilly” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 medical trials together with a Part 2b trial for recurrent GBM, the commonest and uniformly deadly type of mind most cancers. MDNA55 has obtained Quick-Observe and Orphan Drug standing from the FDA and FDA/EMA, respectively.
For additional details about the Firm please contact:
Elizabeth Williams, Chief Monetary Officer, 416-648-5555, firstname.lastname@example.org
For extra investor info, please contact:
Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, email@example.com